Rapid Nutrition Announces Commencement of Production for Azurene Immunity Formula ahead of Northern Hemisphere Winter
London, United Kingdom 31 July 2023 - Rapid Nutrition PLC (Euronext Growth: ALRPD), a globally renowned health and wellness company, is pleased to announce the initiation of production for its highly anticipated Azurene Immunity formula. As Europe braces for the forthcoming winter season, characterised by an anticipated rise in influenza, colds, and coughs, Rapid Nutrition's patented product formula seeks to aid in relief and support to individuals during this critical period.
According to statistical data and trends projected for the pending winter season in Europe, health experts anticipate a notable increase in the prevalence of flu, colds, and coughs. This expected increase in the winter periods underscores the timely release of Azurene to the market as an effective aid to help support the immune system.
The Azurene Immunity formula boasts a patented combination of herbs, drawing from both Western and Chinese herbal medicine traditions, specifically formulated to help provide relief from sore throats, colds, and flu.
Simon St Ledger, CEO of Rapid Nutrition, expressed his enthusiasm for the potential benefits of Azurene in aiding travellers and those in close working environments such as teachers and flight personnel:
"As we approach the winter season, many individuals, particularly frequent travellers and those working in close working environments like teachers and flight attendants, face heightened exposure. The Azurene Immunity formula is designed to be a reliable solution, supporting well-being during these trying times.”
With production now underway, Rapid Nutrition aims to make Azurene available to consumers before the onset of the European winter season. Additional information regarding the product's availability and distribution channels will be disclosed in due course.
About Rapid Nutrition
Dedicated to the development and distribution of premium, science-based health and wellness brands across the globe, Rapid Nutrition shares a wealth of award-winning products with consumers who are passionate about innovations that are “made by nature, refined by science.” Rapid Nutrition’s first-class scientific team matches the experience of its management team to keep both the company and consumers on top of the latest industry trends and developments, while aligning with industry leaders worldwide to deliver effective supplements and solutions. Rapid Nutrition aims to be the supplier of choice globally by offering premium brands with the highest-quality ingredients to deliver maximum results.
For more information, please visit http://rnplc.com
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).